Abstract: |
Graft-v-host disease (GVHD) is a major limitation to the success of bone marrow transplants (BMT) for the treatment of leukemia. Several clinical trials with bone marrow depleted of donor T lymphocytes indicate that both the incidence and severity of GVHD in engrafted patients undergoing BMT for treatment of leukemia are greatly reduced. In comparison to results seen with leukemic recipients of unmodified HLA identical BMTs in which there is a less than 1% incidence of graft rejection, there has been an increased incidence of graft failure or graft rejection among recipients of both HLA identical and HLA nonidentical T cell depleted marrow grafts. Among recipients of HLA identical T cell depleted transplants, the reported incidence of graft failure ranges from 10% to 30%. In our initial series of 20 patients with leukemia who received HLA nonidentical bone marrow depleted of T cells with soybean agglutinin and E-rosettes (SBA-E-), there was, overall, a 50% incidence of graft failure. In order to investigate the nature of graft failure, we have analyzed the clinical features of the patients and characterized by phenotype and functional assays the peripheral blood mononuclear cells (PBMC) present at the time of graft failure. |
Keywords: |
leukemia; human cell; major clinical study; review; t-lymphocytes; bone marrow cells; animal experiment; time factors; leukocytes, mononuclear; cell culture; cytotoxic t lymphocyte; t-lymphocytes, cytotoxic; cytotoxicity, immunologic; hematopoiesis; graft rejection; bone marrow transplantation; antigens, differentiation; human; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; t-lymphocytes, suppressor-effector
|